A case study on how a leading pharma company in hematology turned to DelveInsight for long-term competitive intelligence support. DelveInsight provided an in-depth analysis of competitive activity ...

The pharma company now has two positive proof-of-concept trials under its belt, including its weight-loss pill.

With hundreds of thousands of new cases diagnosed annually, hematologic cancers, such as acute myeloid leukemia (AML), acute ...

A new method can improve treatment for patients with chronic myeloid leukemia by predicting which medication will be most ...

A new method can improve treatment for patients with chronic myeloid leukemia by predicting which medication will be most ...

A new method can improve treatment for patients with chronic myeloid leukaemia by predicting which medication will be most effective. The method also works for other forms of cancer where resistance ...

Dr. Brian Druker's resignation comes after a tumultuous year for OHSU with massive layoffs, the abrupt resignation of President Danny Jacobs and a planned merger.

Targeted Oncology co-hosts Kristie L. Kahl and Andrew Svonavec highlight abstracts for community oncologists to look out for ...

TERN-701 showed promising early results, with significant molecular responses and a strong safety profile in heavily ...

Terns Pharmaceuticals Inc.’s stock jumped 7.5% premarket Tuesday, after the company announced positive data from an ...

Compelling molecular responses starting at lowest dose level in heavily pre-treated patients with high baseline BCR-ABL transcript ...

Terns Pharmaceuticals (TERN) announced encouraging early data from the ongoing dose escalation part of the Phase 1 CARDINAL study evaluating ...